EUVIMEDEUVIMED entdecken
Open Access

Kinetics of EBV antibody‐based NPC risk scores in Taiwan NPC multiplex families

Wan-Lun Hsu, Jun Tao, Sheng Fu, Kelly J Yu, Julia Simon, Tseng-Cheng Chen, Chien-Jen Chen iD, Alisa M Goldstein iD, Kai Yu iD, Allan Hildesheim iD, Tim Waterboer, Cheng-Ping Wang und 1 weitere

International Journal of Cancer · 2024

DOI: 10.1002/ijc.35037 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Wan-Lun Hsu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Data Science Center, College of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan. Hauptthemen laut MEDLINE: Herpesvirus 4, Human, Antibodies, Viral, Epstein-Barr Virus Infections, Nasopharyngeal Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, National Cancer Institute Intramural Research Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nasopharyngeal carcinoma (NPC) risk prediction models based on Epstein–Barr virus (EBV)‐antibody testing have shown potential for screening of NPC; however, the long‐term stability is unclear. Here, we investigated the kinetics of two EBV‐antibody NPC risk scores within the Taiwan NPC Multiplex Family Study. Among 545 participants with multiple blood samples, we evaluated the stability of a 2‐marker enzyme‐linked immunosorbent assay score and 13‐marker multiplex serology score using the intra‐class correlation coefficient (ICC) by fitting a linear mixed model that accounted for the clustering effect of multiple measurements per subject and age. We also estimated the clustering of positive tests using Fleiss's kappa statistic. Over an average 20‐year follow‐up, the 2‐marker score showed high stability over time, whereas the 13‐marker score was more variable ( p < .05). Case–control status is associated with the kinetics of the antibody response, with higher ICCs among cases. Positive tests were more likely to cluster within the same individual for the 2‐marker score than the 13‐marker score ( p < .05). The 2‐marker score had an increase in specificity from ~90% for single measurement to ~96% with repeat testing. The 13‐marker score had a specificity of ~73% for a single measurement that increased to ~92% with repeat testing. Among individuals who developed NPC, none experienced score reversion. Our findings suggest that repeated testing could improve the specificity of NPC screening in high‐risk NPC multiplex families. Further studies are required to determine the impact on sensitivity, establish optimal screening intervals, and generalize these findings to general population settings in high‐risk regions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Herpesvirus 4, HumanAntibodies, ViralEpstein-Barr Virus InfectionsNasopharyngeal NeoplasmsNasopharyngeal CarcinomaHumansTaiwanMaleFemaleAdultMiddle AgedKineticsCase-Control StudiesEnzyme-Linked Immunosorbent AssayYoung AdultRisk FactorsAged

Stichwörter der Autor:innen

EBV biomarkersEpstein–Barr virusantibody kineticscancer screeningnasopharyngeal carcinoma

Substanzen

Antibodies, Viral

Autor:innen und Institutionen

  • Data Science Center, College of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan.
  • College of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan.
  • Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
  • School of Statistics and Data Science, Nankai University, Tianjin, China.
  • Division of Infections and Cancer Epidemiology, German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), Heidelberg, Germany.
  • Department of Otolaryngology, National Taiwan University Hospital and National Taiwan University, College of Medicine, Taipei, Taiwan.

ORCID-Profile: Chien-Jen Chen, Alisa M Goldstein, Kai Yu, Allan Hildesheim, Zhiwei Liu

Förderung

  • Intramural NIH HHS
  • National Cancer Institute Intramural Research Program

Zitieren

APA

Hsu, W. L., Tao, J., Fu, S., Yu, K. J., Simon, J., Chen, T. C., Chen, C. J., Goldstein, A. M., Yu, K., Hildesheim, A., Waterboer, T., Wang, C. P., & Liu, Z. (2024). Kinetics of EBV antibody‐based NPC risk scores in Taiwan NPC multiplex families. International Journal of Cancer. https://doi.org/10.1002/ijc.35037

Vancouver

Hsu WL, Tao J, Fu S, Yu KJ, Simon J, Chen TC, et al. Kinetics of EBV antibody‐based NPC risk scores in Taiwan NPC multiplex families. International Journal of Cancer. 2024. doi:10.1002/ijc.35037

BibTeX
@article{Hsu2024,
  author = {Hsu, Wan-Lun and Tao, Jun and Fu, Sheng and Yu, Kelly J and Simon, Julia and Chen, Tseng-Cheng and Chen, Chien-Jen and Goldstein, Alisa M and Yu, Kai and Hildesheim, Allan and Waterboer, Tim and Wang, Cheng-Ping and Liu, Zhiwei},
  title = {Kinetics of EBV antibody‐based NPC risk scores in Taiwan NPC multiplex families},
  journal = {International Journal of Cancer},
  year = {2024},
  doi = {10.1002/ijc.35037}
}
Kostenlos starten →